Effects of HER2 overexpression on cell signaling networks governing proliferation and migration

[1]  P. Uetz,et al.  The interactome of human EGF/ErbB receptors , 2006, Molecular systems biology.

[2]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[3]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[4]  D. Lauffenburger,et al.  Autocrine EGF receptor activation mediates endothelial cell migration and vascular morphogenesis induced by VEGF under interstitial flow. , 2005, Experimental cell research.

[5]  D. Lauffenburger,et al.  A Compendium of Signals and Responses Triggered by Prodeath and Prosurvival Cytokines*S , 2005, Molecular & Cellular Proteomics.

[6]  D. Yee,et al.  Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration , 2005, Breast Cancer Research and Treatment.

[7]  D. Lauffenburger,et al.  Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules*S , 2005, Molecular & Cellular Proteomics.

[8]  W. R. Bishop,et al.  Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody , 2005, Molecular Cancer Therapeutics.

[9]  K. K. Jacob,et al.  Integrin activates receptor-like protein tyrosine phosphatase alpha, Src, and Rho to increase prolactin gene expression through a final phosphatidylinositol 3-kinase/cytoskeletal pathway that is additive with insulin. , 2005, Endocrinology.

[10]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[11]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[12]  D. Lauffenburger,et al.  Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells* , 2005, Journal of Biological Chemistry.

[13]  R. Roskoski,et al.  Src protein-tyrosine kinase structure and regulation. , 2004, Biochemical and biophysical research communications.

[14]  I. Madshus,et al.  Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. , 2004, Experimental cell research.

[15]  Michael D Schaller,et al.  The interplay between Src and integrins in normal and tumor biology , 2004, Oncogene.

[16]  M. Stack,et al.  Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells* , 2004, Journal of Biological Chemistry.

[17]  S. Steurer,et al.  Vascular Endothelial Growth Factor Receptor-2–Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase Receptor , 2004, Circulation research.

[18]  K. Wester,et al.  HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review , 2004, British Journal of Cancer.

[19]  A. Reynolds,et al.  EGFR signaling to p120-catenin through phosphorylation at Y228 , 2004, Journal of Cell Science.

[20]  Donna J. Webb,et al.  FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly , 2004, Nature Cell Biology.

[21]  V. Margaria,et al.  P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading. , 2003, Molecular biology of the cell.

[22]  Albert B. Reynolds,et al.  A core function for p120-catenin in cadherin turnover , 2003, The Journal of cell biology.

[23]  K. Bloom,et al.  The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. , 2003, The oncologist.

[24]  J. Baselga,et al.  Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jaakko Astola,et al.  Analysis and Visualization of Gene Expression Microarray Data in Human Cancer Using Self-Organizing Maps , 2003, Machine Learning.

[27]  D. Lauffenburger,et al.  Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis , 2003, Journal of Biological Chemistry.

[28]  Maria D Person,et al.  Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration , 2003, Oncogene.

[29]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[30]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[31]  Douglas Lauffenburger,et al.  Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. , 2003, Cancer research.

[32]  R. Lupu,et al.  Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer , 2003, Oncogene.

[33]  M. Welsh,et al.  The Shb adaptor protein causes Src-dependent cell spreading and activation of focal adhesion kinase in murine brain endothelial cells. , 2003, Cellular signalling.

[34]  A. Tsubouchi,et al.  Localized suppression of RhoA activity by Tyr31/118-phosphorylated paxillin in cell adhesion and migration , 2002, The Journal of cell biology.

[35]  G. Yancopoulos,et al.  Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. , 2002, Molecular cancer research : MCR.

[36]  Ling Xia,et al.  Identification of Both Positive and Negative Domains within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation* , 2002, The Journal of Biological Chemistry.

[37]  B. Tycko,et al.  Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation , 2002, Molecular Cancer.

[38]  D. Webb,et al.  GIT1 functions in a motile, multi-molecular signaling complex that regulates protrusive activity and cell migration. , 2002, Journal of cell science.

[39]  Jun Yao,et al.  Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-β1 in human breast cancer cells , 2001, Oncogene.

[40]  H. Chung,et al.  Expression and Tyrosine Phosphorylation of E-Cadherin, β- and γ-Catenin, and Epidermal Growth Factor Receptor in Cervical Cancer Cells☆ , 2001 .

[41]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[42]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[43]  Jie Leng,et al.  ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases , 2000, The Journal of cell biology.

[44]  M. Sliwkowski,et al.  Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells , 1999, Oncogene.

[45]  G. Feng,et al.  Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Guan,et al.  Focal adhesion kinase in integrin-mediated signaling. , 1999, Frontiers in bioscience : a journal and virtual library.

[47]  M. Farthing,et al.  The E‐cadherin/epidermal growth factor receptor interaction: a hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation , 1999, The Journal of pathology.

[48]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[49]  B. Rothhut.  Participation of annexins in protein phosphorylation , 1997, Cellular and Molecular Life Sciences CMLS.

[50]  A. Sorkin,et al.  Epidermal Growth Factor Receptor Interaction with Clathrin Adaptors Is Mediated by the Tyr974-containing Internalization Motif* , 1996, The Journal of Biological Chemistry.

[51]  H. Erickson,et al.  Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. , 1996, Molecular biology of the cell.

[52]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[53]  T. Kohonen.  Self-Organizing Maps , 1995, Springer Series in Information Sciences.

[54]  M. Cobb,et al.  The mitogen-activated protein kinases, ERK1 and ERK2. , 1994, Seminars in cancer biology.

[55]  J. Taylor‐Papadimitriou,et al.  Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Y. Kido,et al.  Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. , 1994, The Journal of biological chemistry.

[57]  M. Stampfer,et al.  Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo[a]pyrene. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Nikhil V. Shirahatti,et al.  Actin microfilament aggregation induced by withaferin A is mediated by annexin II , 2006, Nature chemical biology.

[59]  John G. Albeck,et al.  Cue-Signal-Response Analysis of TNF-Induced Apoptosis by Partial Least Squares Regression of Dynamic Multivariate Data , 2004, J. Comput. Biol..

[60]  M. Kinch,et al.  Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer , 2004, Clinical & Experimental Metastasis.

[61]  Hou-qi Liu,et al.  SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1 βin vivo andin vitro , 2004, Breast Cancer Research and Treatment.

[62]  R. Lupu,et al.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.

[63]  M. Lemmon.  The EGF receptor family as therapeutic targets in breast cancer. , 2003, Breast disease.

[64]  H. Park,et al.  Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells. , 2001, Gynecologic oncology.

[65]  Esa Alhoniemi,et al.  SOM Toolbox for Matlab 5 , 2000 .

[66]  Jie Leng,et al.  ErbB 2 Is Necessary for Induction of Carcinoma Cell Invasion by ErbB Family Receptor Tyrosine Kinases , 2000 .